Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 2/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442673 | 0.80 | MLLT1 (0.34) | MLLT1DGAT2JAK2JAK1CACNA1H | |
| SCHEMBL7449699 | 0.75 | MLLT1 (0.38) | MLLT1DGAT2TGFBR1 | |
| SCHEMBL7448201 | 0.74 | EPHX2 (0.39) | MLLT1DGAT2TGFBR1 | |
| SCHEMBL6455937 | 0.73 | F2 (0.42) | — | |
| SCHEMBL6450639 | 0.73 | F2 (0.42) | — | |
| Hydrochloric Acid SCHEMBL6451914 | 0.73 | F2 (0.41) | — | |
| SCHEMBL7445643 | 0.71 | NPC1 (0.35) | MLLT1DGAT2TGFBR1 | |
| SCHEMBL7454489 | 0.71 | NPC1 (0.38) | MLLT1DGAT2CACNA1BTGFBR1 | |
| SCHEMBL7447136 | 0.71 | ALDH1A1 (0.37) | MLLT1DGAT2CACNA1BTGFBR1 | |
| SCHEMBL7421109 | 0.70 | NPC1 (0.37) | MLLT1DGAT2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517687-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000310-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | disclosed |